Short Interest in TransMedics Group, Inc. (NASDAQ:TMDX) Increases By 30.9%

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 8,430,000 shares, a growth of 30.9% from the October 15th total of 6,440,000 shares. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is currently 6.1 days.

TransMedics Group Price Performance

Shares of TransMedics Group stock traded down $7.88 on Friday, reaching $80.48. The company's stock had a trading volume of 2,305,980 shares, compared to its average volume of 969,652. The company has a market capitalization of $2.70 billion, a P/E ratio of 85.62 and a beta of 2.08. The stock has a 50-day moving average price of $125.63 and a 200-day moving average price of $139.09. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a 52-week low of $63.85 and a 52-week high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts' expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm's revenue for the quarter was up 63.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) EPS. Analysts expect that TransMedics Group will post 1.07 EPS for the current year.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company's stock, valued at approximately $9,457,269.06. This represents a 12.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Nicholas Corcoran sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company's stock, valued at $3,714,902.10. The trade was a 32.15 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its holdings in shares of TransMedics Group by 35.1% during the first quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company's stock worth $1,286,000 after buying an additional 4,518 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of TransMedics Group by 337,462.5% in the 1st quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company's stock valued at $1,997,000 after buying an additional 26,997 shares during the period. ProShare Advisors LLC grew its position in TransMedics Group by 7.8% in the first quarter. ProShare Advisors LLC now owns 5,871 shares of the company's stock worth $434,000 after acquiring an additional 427 shares during the period. Entropy Technologies LP purchased a new position in shares of TransMedics Group during the 1st quarter worth $201,000. Finally, State Board of Administration of Florida Retirement System boosted its position in shares of TransMedics Group by 8.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company's stock worth $745,000 after purchasing an additional 780 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMDX has been the subject of a number of analyst reports. Robert W. Baird decreased their price objective on TransMedics Group from $200.00 to $150.00 and set an "outperform" rating for the company in a research note on Tuesday, October 29th. Needham & Company LLC decreased their price objective on TransMedics Group from $208.00 to $109.00 and set a "buy" rating for the company in a report on Tuesday, October 29th. Stephens increased their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. Canaccord Genuity Group decreased their target price on TransMedics Group from $169.00 to $109.00 and set a "buy" rating for the company in a report on Tuesday, October 29th. Finally, Oppenheimer cut their price target on TransMedics Group from $200.00 to $125.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group currently has an average rating of "Buy" and a consensus target price of $144.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.